BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks

Reuters01-27

BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks

** Citigroup initiates ratings on European large-cap pharma, noting steady EPS growth, a strong pipeline that more than offsets patent losses, a catalyst-heavy year, easing U.S. pricing risks and rerating potential

** It starts Novartis NOVN.S with a "buy" rating calling the Swiss group a "consistent earnings outperformer" with several potential multi‑billion‑dollar drugs

** It also rates Roche ROG.S with "buy" as its pipeline is recovering, backed by positive Phase III results and an undervalued breast‑cancer drug Citi sees as much larger than consensus

** The two are Citi's top picks

** Citi initiates AstraZeneca AZN.L with "buy", seeing the strongest growth and pipeline in the sector, with $46 billion in late‑stage potential, major 2026 catalysts and several under‑appreciated assets in consensus

** GSK GSK.L is rated "neutral" as its improved operational performance, capital allocation and pipeline in recent years are still trumped by its LOE exposure from 2028

** Sanofi SASY.PA is "neutral" after a run of pipeline setbacks, which are priced in, but leave limited R&D momentum for rerating

** Novo Nordisk NOVOb.CO is "neutral" amid pricing, access and competitive pressures in GLP‑1s offset by early strong Wegovy pill launch

(Reporting by Elviira Luoma)

((Elviira.luoma@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606783612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606783612","market":"nz","top_or_hot":-1,"title":"BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks</title></head><body><p>** Citigroup <span>initiates ratings on</span> European large-cap pharma, noting steady EPS growth, a strong pipeline that more than offsets patent losses, a catalyst-heavy year, easing U.S. pricing risks and rerating <span>potential</span></p><p>** It starts Novartis <span>NOVN.S</span> with a \"buy\" rating <span>calling the Swiss group</span> a \"consistent earnings outperformer\" with several potential multi‑billion‑dollar drugs </p><p>** It also rates Roche <span>ROG.S</span> with \"buy\" as its pipeline is recovering, backed by positive Phase III results and an undervalued breast‑cancer drug Citi sees as much larger than consensus</p><p>** The two are Citi's top picks</p><p>** Citi initiates AstraZeneca <span>AZN.L</span> with \"buy\", seeing the strongest growth and pipeline in the <span>sector</span>, with $46 billion in late‑stage potential, major 2026 catalysts and several under‑appreciated assets in consensus</p><p>** GSK <span>GSK.L</span> is rated \"neutral\" as its improved operational performance, capital allocation and pipeline in recent years are still trumped by its LOE exposure from 2028</p><p>** <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> <span>SASY.PA</span> is \"neutral\" after a run of pipeline setbacks, which are priced in, but leave limited R&amp;D momentum for rerating</p><p>** <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>NOVOb.CO</span> is \"neutral\" amid pricing, access and competitive pressures in GLP‑1s offset by early strong Wegovy pill launch</p><p> (Reporting by Elviira Luoma)</p><p> ((Elviira.luoma@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-27 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks</title></head><body><p>** Citigroup <span>initiates ratings on</span> European large-cap pharma, noting steady EPS growth, a strong pipeline that more than offsets patent losses, a catalyst-heavy year, easing U.S. pricing risks and rerating <span>potential</span></p><p>** It starts Novartis <span>NOVN.S</span> with a \"buy\" rating <span>calling the Swiss group</span> a \"consistent earnings outperformer\" with several potential multi‑billion‑dollar drugs </p><p>** It also rates Roche <span>ROG.S</span> with \"buy\" as its pipeline is recovering, backed by positive Phase III results and an undervalued breast‑cancer drug Citi sees as much larger than consensus</p><p>** The two are Citi's top picks</p><p>** Citi initiates AstraZeneca <span>AZN.L</span> with \"buy\", seeing the strongest growth and pipeline in the <span>sector</span>, with $46 billion in late‑stage potential, major 2026 catalysts and several under‑appreciated assets in consensus</p><p>** GSK <span>GSK.L</span> is rated \"neutral\" as its improved operational performance, capital allocation and pipeline in recent years are still trumped by its LOE exposure from 2028</p><p>** <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> <span>SASY.PA</span> is \"neutral\" after a run of pipeline setbacks, which are priced in, but leave limited R&amp;D momentum for rerating</p><p>** <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>NOVOb.CO</span> is \"neutral\" amid pricing, access and competitive pressures in GLP‑1s offset by early strong Wegovy pill launch</p><p> (Reporting by Elviira Luoma)</p><p> ((Elviira.luoma@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109981661.USD","symbol_name":"FRANKLIN MUTUAL EUROPEAN \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL8N3YS0S9:1","article_id":"2606783612","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606783612","pubTimestamp":1769511588,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks** Citigroup initiates ratings on European large-cap pharma, noting steady EPS growth, a strong pipeline that more than offsets patent losses, a catalyst-heavy year, easing U.S. pricing risks and rerating potential** It starts Novartis NOVN.S with a \"buy\" rating calling the Swiss group a \"consistent earnings outperformer\" with several potential multibilliondollar drugs ** It also rates Roche ROG.S with \"buy\" as its pipeline is recovering, backed by positive Phase III results and an undervalued breastcancer drug Citi sees as much larger than consensus** The two are Citi's top picks** Citi initiates AstraZeneca AZN.L with \"buy\", seeing the strongest growth and pipeline in the sector, with $46 billion in latestage potential, major 2026 catalysts and several underappreciated assets in consensus** GSK GSK.L is rated \"neutral\" as its improved operational performance, capital allocation and pipeline in recent years are still","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109981661.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USD) ACC","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU1400636574.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AMG\" (HKDHDG) INC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU1309081286.SGD":"SCHRODER ISF EUROPEAN VALUE \"A\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2293690249.USD":"SCHRODER ISF EUROPEAN SUSTAINABLE EQUITY \"A\" (USDHDG) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BSX":"波士顿科学","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0171293334.USD":"贝莱德英国基金A2","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","03165":"华夏欧优股对冲","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1400636657.SGD":"Allianz Europe Income and Growth Cl AMg DIS H2-SGD","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","GSK.UK":"葛兰素史克","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0920840948.USD":"安联欧洲股票增长精选Cl AT Acc","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1046248800.SGD":"Allianz European Equity Dividend Cl AM DIS H2-SGD","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0857590862.USD":"ALLIANZ EUROPE EQUITY GROWTH \"AT\" (USDHDG) H2 ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","AZN.UK":"阿斯利康制药","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC"},"translate_title":"嗡嗡声——花旗看好欧洲制药公司；阿斯利康、诺华首选","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.9,"03165":0.6,"AZN.UK":0.9,"BSX":0.9},"content_text":"BUZZ-Citi bullish on European pharma; AstraZeneca, Novartis top picks** Citigroup initiates ratings on European large-cap pharma, noting steady EPS growth, a strong pipeline that more than offsets patent losses, a catalyst-heavy year, easing U.S. pricing risks and rerating potential** It starts Novartis NOVN.S with a \"buy\" rating calling the Swiss group a \"consistent earnings outperformer\" with several potential multi‑billion‑dollar drugs ** It also rates Roche ROG.S with \"buy\" as its pipeline is recovering, backed by positive Phase III results and an undervalued breast‑cancer drug Citi sees as much larger than consensus** The two are Citi's top picks** Citi initiates AstraZeneca AZN.L with \"buy\", seeing the strongest growth and pipeline in the sector, with $46 billion in late‑stage potential, major 2026 catalysts and several under‑appreciated assets in consensus** GSK GSK.L is rated \"neutral\" as its improved operational performance, capital allocation and pipeline in recent years are still trumped by its LOE exposure from 2028** Sanofi SASY.PA is \"neutral\" after a run of pipeline setbacks, which are priced in, but leave limited R&D momentum for rerating** Novo Nordisk NOVOb.CO is \"neutral\" amid pricing, access and competitive pressures in GLP‑1s offset by early strong Wegovy pill launch (Reporting by Elviira Luoma) ((Elviira.luoma@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606783612","isCrawlerRequest":true}